Literature DB >> 15811965

FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs.

Bridget M Kuehn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15811965     DOI： 10.1001/jama.293.13.1571

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

Review 1.  An evidence-based update on nonsteroidal anti-inflammatory drugs.

Authors:  C K S Ong; P Lirk; C H Tan; R A Seymour
Journal:  Clin Med Res       Date:  2007-03

Review 2.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

3.  Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

Authors:  M Hassan-Alin; J Naesdal; C Nilsson-Pieschl; G Långström; T Andersson
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

4.  Accounting for the increase in NSAID expenditure: substitution or leakage?

Authors:  Garry R Barton; Anthony J Avery; David K Whynes
Journal:  Cost Eff Resour Alloc       Date:  2006-05-31

5.  Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database.

Authors:  Chieko Ishiguro; Toshiharu Fujita; Takashi Omori; Yosuke Fujii; Takeshi Mayama; Tosiya Sato
Journal:  J Epidemiol       Date:  2008-05-09       Impact factor: 3.211
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.